Molecular targets in gynaecological cancers

Pathology

Volumn 39, Issue 1, 2007, Pages 26-45

  Cheung, Annie N Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Expression profiling; HPV; Individualised therapy; Methylation; Molecular targets; Telomerase

Indexed keywords

ANGIOGENESIS INHIBITOR; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HER2 PROTEIN INHIBITOR; IMATINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16INK4A; PROTEIN TYROSINE KINASE INHIBITOR; RNA; TELOMERASE; TRANSCRIPTOME; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CARCINOGENESIS; CARCINOMATOUS PERITONITIS; CLINICAL LABORATORY; CLINICAL MEDICINE; CYTOLOGY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; ENZYME ACTIVITY; FOLLOW UP; GENE EXPRESSION PROFILING; GENOMICS; GYNECOLOGIC CANCER; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; MEDICAL ETHICS; MEDICAL RESEARCH; METHYLATION; MICROARRAY ANALYSIS; MOLECULAR CLONING; MOLECULAR DYNAMICS; OVARY CANCER; PATHOLOGY; PROGNOSIS; PROTEIN MICROARRAY; QUALITY CONTROL; REVIEW; SIGNAL TRANSDUCTION; SMEAR; SQUAMOUS CELL CARCINOMA; TARGET VARIABLE; TISSUE MICROARRAY; TREATMENT OUTCOME; TROPHOBLASTIC TUMOR; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERUS CARCINOMA; VIRUS DETECTION; VIRUS TYPING; WART VIRUS;

EID: 33847229125     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020601153273     Document Type: Article

References (281)

1. Shih Ie M, Wang TL. Apply innovative technologies to explore cancer genome. Curr Opin Oncol 2005; 17: 33-8.
2. Dietel M, Sers C. Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch 2006; 448: 744-55.
3. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001; 10: 657-62.
4. van de Rijn M, Gilks CB. Applications of microarrays to histopathology. Histopathology 2004; 44: 97-108.
5. Russo G, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. Oncogene 2003; 22: 6497-507.
6. Bandera CA, Ye B, Mok SC. New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 2003; 15: 51-5.
7. Espina V, Dettloff KA, Cowherd S, Petricoin EF 3rd, Liotta LA. Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther 2004; 4: 83-93.
8. Pappa KI, Anagnou NP. Emerging issues of the expression profiling technologies for the study of gynecologic cancer. Am J Obstet Gynecol 2005; 193: 908-18.
9. Espina V, Geho D, Mehta AI, et al. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest 2005; 23: 36-46.
10. Horvath L, Henshall S. The application of tissue microarrays to cancer research. Pathology 2001; 33: 125-9.
11. Giltnane JM, Rimm DL. Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol 2004; 1: 104-11.
12. Dimova I, Yosifova A, Zaharieva B, et al. Association of 20q13.2 copy number changes with the advanced stage of ovarian cancer-tissue microarray analysis. Eur J Obstet Gynecol Reprod Biol 2005; 118: 81-5.
13. Downie D, McFadyen MC, Rooney PH, et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res 2005; 11: 7369-75.
14. Ouellet V, Guyot MC, Le Page C, et al. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 2006; 119: 599-607.
15. Zhang L, Huang J, Yang N, et al. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res 2006; 66: 4627-35.
16. Lassus H, Sihto H, Leminen A, et al. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med 2006; 84: 671-81.
17. Mayr D, Kanitz V, Anderegg B, et al. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol 2006; 126: 101-9.
18. Rosen DG, Huang X, Deavers MT, et al. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 2004; 17: 790-7.
19. Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999; 238: 375-85.
20. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001; 98: 1176-81.
21. Tapper J, Kettunen E, El-Rifai W, et al. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet 2001; 128: 1-6.
22. Xie D, Lau SH, Sham JS, et al. Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer 2005; 103: 277-83.
23. Ouellet V, Provencher DM, Maugard CM, et al. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 2005; 24: 4672-87.
24. Adib TR, Henderson S, Perrett C, et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004; 90: 686-92.
25. Sheehan KM, Calvert VS, Kay EW, et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005; 4: 346-55.
26. Gulmann C, Sheehan KM, Kay EW, Liotta LA, Petricoin EF 3rd. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J Pathol 2006; 208: 595-606.
27. Duan Z, Foster R, Bell DA, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006; 12: 5055-63.
28. Armes JE, Lourie R, de Silva M, et al. Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int J Gynecol Pathol 2005; 24: 363-8.
29. Haviv I, Campbell IG. DNA microarrays for assessing ovarian cancer gene expression. Mol Cell Endocrinol 2002; 191: 121-6.
30. Nishizuka S, Chen ST, Gwadry FG, et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 2003; 63: 5243-50.
31. Crijns AP, Duiker EW, de Jong S, et al. Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. Int J Gynecol Cancer 2006; 16 (Suppl 1): 152-65.
32. Lassus H, Leminen A, Vayrynen A, et al. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 2004; 92: 31-9.
33. Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol 2004; 95: 570-5.
34. Rosen DG, Yang G, Deavers MT, et al. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 2006; 106: 1925-32.
35. Smid-Koopman E, Blok LJ, Chadha-Ajwani S, et al. Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method. Br J Cancer 2000; 83: 246-51.
36. Moreno-Bueno G, Sanchez-Estevez C, Cassia R, et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003; 63: 5697-702.
37. Cao QJ, Belbin T, Socci N, et al. Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. Int J Gynecol Pathol 2004; 23: 321-9.
38. Li SS, Xue WC, Khoo US, et al. Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis. Histopathology 2005; 46: 307-13.
39. Chan QK, Khoo US, Chan KY, et al. Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma. J Mol Diagn 2005; 7: 8-16.
40. Hardisson D, Moreno-Bueno G, Sanchez L, et al. Tissue microarray immunohistochemical expression analysis of mismatch repair (hMLH1 and hMSH2 genes) in endometrial carcinoma and atypical endometrial hyperplasia: relationship with microsatellite instability. Mod Pathol 2003; 16: 1148-58.
41. Dupont J, Wang X, Marshall DS, et al. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol 2004; 94: 449-55.
42. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004; 22: 1242-52.
43. Chitale DA, Jungbluth AA, Marshall DS, et al. Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. Mod Pathol 2005; 18: 119-26.
44. Pallares J, Martinez-Guitarte JL, Dolcet X, et al. Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J Pathol 2004; 204: 569-77.
45. Morrison C, Zanagnolo V, Ramirez N, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 2006; 24: 2376-85.
46. Shim C, Zhang W, Rhee CH, Lee JH. Profiling of differentially expressed genes in human primary cervical cancer by complementary DNA expression array. Clin Cancer Res 1998; 4: 3045-50.
47. Contag SA, Gostout BS, Clayton AC, et al. Comparison of gene expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Gynecol Oncol 2004; 95: 610-7.
48. Chao A, Wang TH, Lee YS, et al. Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int J Cancer 2006; 119: 91-8.
49. Steinau M, Lee DR, Rajeevan MS, et al. Gene expression profile of cervical tissue compared to exfoliated cells: impact on biomarker discovery. BMC Genomics 2005; 6: 64.
50. Alkushi A, Irving J, Hsu F, et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 2003; 442: 271-7.
51. Hennessy BT, Mills GB. Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signaling. Int J Biochem Cell Biol 2006; 38: 1450-6.
52. See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer 2003; 13: 701-34.
53. Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, et al. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2006; 32: 180-90.
54. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-99.
55. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
56. van Haaften-Day C, Russell P, Boyer CM, et al. Expression of cell regulatory proteins in ovarian borderline tumors. Cancer 1996; 77: 2092-98.
57. Hougardy BM, Maduro JH, van der Zee AG, Willemse PH, de Jong S, de Vries EG. Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance. Lancet Oncol 2005; 6: 589-98.
58. van Dam PA, Vergote IB, Lowe DG, et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol 1994; 47: 914-9.
59. Felip E, Del Campo JM, Rubio D, et al. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 1995; 75: 2147-52.
60. Leeson SC, Morphopoulos G, Buckley CH, Hale RJ. c-erbB-2 oncogene expression in Stage I epithelial ovarian cancer. Br J Obstet Gynaecol 1995; 102: 65-7.
61. Anreder MB, Freeman SM, Merogi A, Halabi S, Marrogi AJ. p53, c-erbB2, and PCNA status in benign, proliferative and malignant ovarian surface epithelial neoplasms: a study of 75 cases. Arch Pathol Lab Med 1999; 123: 310-6.
62. Ross JS, Yang F, Kallakury BV, et al. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am J Clin Pathol 1999; 111: 311-6.
63. Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 283-90.
64. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23: 2534-43.
65. Simpson BJ, Phillips HA, Lessells AM, Langdon SP, Miller WR. c-erbB growth-factor-receptor proteins in ovarian tumours. Int J Cancer 1995; 64: 202-6.
66. Rusnak DW, Affleck K, Cockerill SG, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001; 61: 7196-203.
67. Monk BJ, Chapman JA, Johnson GA, et al. Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. Am J Obstet Gynecol 1994; 171: 1193-8.
68. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994; 53: 84-92.
69. Czerwenka K, Lu Y, Heuss F. Amplification and expression of the c-erbB-2 oncogene in normal, hyperplastic, and malignant endometria. Int J Gynecol Pathol 1995; 14: 98-106.
70. Prat J, Oliva E, Lerma E, Vaquero M, Matias-Guiu X. Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer 1994; 74: 1778-83.
71. Ioffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 1998; 29: 1150-9.
72. Santin AD, Zhan F, Cane S, et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer 2005; 92: 1561-73.
73. Santin AD, Bellone S, Siegel ER, et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/ neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol 2005; 192: 813-8.
74. Slomovitz BM, Broaddus RR, Burke TW, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004; 22: 3126-32.
75. Pisani AL, Barbuto DA, Chen D, et al. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995; 85: 729-34.
76. Esteller M, Garcia A, Martinez I, Palones JM, Cabero A, Reventos J. Detection of c-erbB-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction. Cancer 1995; 75: 2139-46.
77. Reinartz JJ, George E, Lindgren BR, Niehans GA. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994; 25: 1075-83.
78. Santini D, Ceccarelli C, Martinelli GN, et al. Immunocytochemical study of epidermal growth factor receptor, transforming growth factor alpha, and 'squamous differentiation' in human endometrial carcinoma. Hum Pathol 1994; 25: 1319-23.
79. Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 2006; 58: 242-56.
80. Ngan HY, Liu SS, Yu H, Liu KL, Cheung AN. Proto-oncogenes and p53 protein expression in normal cervical stratified squamous epithelium and cervical intra-epithelial neoplasia. Eur J Cancer 1999; 35: 1546-50.
81. Kersemaekers AM, Fleuren GJ, Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999; 5: 577-86.
82. Sharma A, Pratap M, Sawhney VM, et al. Frequent amplification of C-erbB2 (HER-2/Neu) oncogene in cervical carcinoma as detected by non-fluorescence in situ hybridization technique on paraffin sections. Oncology 1999; 56: 83-7.
83. Nevin J, Laing D, Kaye P, et al. The significance of Erb-b2 immunostaining in cervical cancer. Gynecol Oncol 1999; 73: 354-8.
84. Nakano T, Oka K, Ishikawa A, Morita S. Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer 1997; 79: 513-20.
85. Nishioka T, West CM, Gupta N, et al. Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy. J Cancer Res Clin Oncol 1999; 125: 96-100.
86. Hunt CR, Hale RJ, Armstrong C, et al. c-erbB-3 proto-oncogene expression in uterine cervical carcinoma. Int J Gynecol Cancer 1995; 5: 282-5.
87. Lee CM, Shrieve DC, Zempolich KA, et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 2005; 99: 415-21.
88. Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A, et al. HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 2004; 4: 59.
89. Pillai MR, Jayaprakash PG, Nair MK. Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. J Cancer Res Clin Oncol 1998; 124: 456-61.
90. Nasu S, Ang KK, Fan Z, Milas L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001; 51: 474-7.
91. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-7.
92. Besson A, Robbins SM, Yong VW. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J Biochem 1999; 263: 605-11.
93. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-90.
94. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39.
95. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/ Akt and apoptosis: size matters. Oncogene 2003; 22: 8983-98.
96. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 2003; 10: 203-8.
97. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-63.
98. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3: 371-7.
99. Hashemolhosseini S, Nagamine Y, Morley SJ, et al. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998; 273: 14424-9.
100. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21: 99-102.
101. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64: 7678-81.
102. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997; 57: 4736-8.
103. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92: 924-30.
104. An HJ, Lee YH, Cho NH, et al. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology 2002; 41: 437-45.
105. Zhou C, Gehrig PA, Whang YE, Boggess JF. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther 2003; 2: 789-95.
106. Soliman P, Schmeler KM, Broaddus RR, et al. mTOR inhibition as a potential treatment for progesterone refractory endometrial hyperplasia. Proc Am Soc Clin Oncol 2005; 23: 5080.
107. Ueda M, Terai Y, Kanda K, et al. Tumor angiogenesis and molecular target therapy in ovarian carcinomas. Hum Cell 2005; 18: 1-16.
108. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 2005; 5: 355-66.
109. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 2004; 64: 3550-8.
110. Raab SS. Human papillomavirus reporting: impact on Bethesda cytology reports. Arch Pathol Lab Med 2003; 127: 969-72.
111. International Agency for Research on Cancer. Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 64. Lyon: IARC. 1995; 64.
112. National Institutes of Health. Cervical Cancer. NIH Consensus Statement 1996; 14: 1-38.
113. Lorincz AT, Reid R, Jenson AB, et al. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992; 79: 328-37.
114. Richart RM, Masood S, Syrjanen KJ, et al. Human papillomavirus. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial. Acta Cytol 1998; 42: 50-8.
115. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796-802.
116. Walboomers JM, Jacobs MV, Manos MM, et al. Human papilloma-virus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
117. Arends MJ, Buckley CH, Wells M. Aetiology, pathogenesis, and pathology of cervical neoplasia. J Clin Pathol 1998; 51: 96-103.
118. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-65.
119. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
120. Koutsky LA, Harper DM. Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine 2006; 24 (Suppl 3): S114-21.
121. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8.
122. Autillo-Touati A, Joannes M, d'Ercole C, et al. HPV typing by in situ hybridization on cervical cytologic smears with ASCUS. Acta Cytol 1998; 42: 631-8.
123. Huang CC, Qiu JT, Kashima ML, Kurman RJ, Wu TC. Generation of type-specific probes for the detection of single-copy human papillomavirus by a novel in situ hybridization method. Mod Pathol 1998; 11: 971-7.
124. Ngan HY, Cheung AN, Liu SS, Liu KL, Tsao SW. Telomerase assay and HPV 16/18 typing as adjunct to conventional cytological cervical cancer screening. Tumour Biol 2002; 23: 87-92.
125. Huang FY, Chiu PM, Tam KF, et al. Semi-quantitative fluorescent PCR analysis identifies PRKAA1 on chromosome 5 as a potential candidate cancer gene of cervical cancer. Gynecol Oncol 2006; 103: 219-25.
126. Ngan HY, Cheung AN, Liu SS, Yip PS, Tsao SW. Abnormal expression or mutation of TP53 and HPV in vulvar cancer. Eur J Cancer 1999; 35: 481-4.
127. Cope JU, Hildesheim A, Schiffman MH, et al. Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens. J Clin Microbiol 1997; 35: 2262-5.
128. Poljak M, Brencic A, Seme K, Vince A, Marin IJ. Comparative evaluation of first- and second-generation digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer. J Clin Microbiol 1999; 37: 796-7.
129. Peyton CL, Schiffman M, Lorincz AT, et al. Comparison of PCR-and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol 1998; 36: 3248-54.
130. Schiffman MH, Kiviat NB, Burk RD, et al. Accuracy and interlaboratory reliability of human papillomavirus DNA testing by hybrid capture. J Clin Microbiol 1995; 33: 545-50.
131. Sherman ME, Schiffman MH, Lorincz AT, et al. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. Cancer 1997; 81: 89-97.
132. Castle PE, Sadorra M, Garcia F, Holladay EB, Kornegay J. Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology. J Clin Microbiol 2006; 44: 3915-7.
133. Stevens MP, Garland SM, Tabrizi SN. Human papillomavirus genotyping using a modified linear array detection protocol. J Virol Methods 2006; 135: 124-6.
134. Cuschieri KS, Cubie HA, Whitley MW, et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol 2005; 58: 946-50.
135. Kim KH, Yoon MS, Na YJ, et al. Development and evaluation of a highly sensitive human papillomavirus genotyping DNA chip. Gynecol Oncol 2006; 100: 38-43.
136. Gheit T, Landi S, Gemignani F, et al. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol 2006; 44: 2025-31.
137. Cheung AN, Szeto EF, Ng KM, et al. Atypical squamous cells of undetermined significance on cervical smears: follow-up study of an Asian screening population. Cancer 2004; 102: 74-80.
138. Kinney WK, Manos MM, Hurley LB, Ransley JE. Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol 1998; 91: 973-6.
139. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999; 281: 1605-10.
140. Ronnett BM, Manos MM, Ransley JE, et al. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum Pathol 1999; 30: 816-25.
141. Bavin PJ, Giles JA, Deery A, et al. Use of semi-quantitative PCR for human papillomavirus DNA type 16 to identify women with high grade cervical disease in a population presenting with a mildly dyskaryotic smear report. Br J Cancer 1993; 67: 602-5.
142. Nuovo GJ. Detection of human papillomavirus in Papanicolaou smears: correlation with pathologic findings and clinical outcome. Diagn Mol Pathol 1998; 7: 158-63.
143. Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G. Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol 2000; 95: 821-7.
144. Cox JT, Lorincz AT, Schiffman MH, et al. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995; 172: 946-54.
145. Cox JT. Evaluating the role of HPV testing for women with equivocal Papanicolaou test findings. JAMA 1999; 281: 1645-7.
146. Wright TC, Jr, Lorincz A, Ferris DG, et al. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol 1998; 178: 962-6.
147. Department of Health and Human Services, Division of STD Prevention, Prevention of genital HPV Infection and Sequelae: Report of an External Consultants' Meeting. Altanta: Centres for Disease Control and Prevention (CDC), 1999. http://www.cdc.gov/nchstp/dstd/Reports_Publications/99HPVReport.htm
148. Jenkins D, Sherlaw-Johnson C, Gallivan S. Can papilloma virus testing be used to improve cervical cancer screening? Int J Cancer 1996; 65: 768-773.
149. Schneider A, Zahm DM, Kirchmayr R, Schneider VL. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection. Am J Obstet Gynecol 1996; 174: 1534-41.
150. van Ballegooijen M, van den Akker-van Marle ME, Warmerdam PG, et al. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. Br J Cancer 1997; 76: 651-7.
151. Cuzick J, Beverley E, Ho L, et al. HPV testing in primary screening of older women. Br J Cancer 1999; 81: 554-8.
152. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 1871-6.
153. Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006; 24 (Suppl 3): S171-7.
154. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765-74.
155. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 547-55.
156. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994; 271: 1866-9.
157. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992; 327: 1272-8.
158. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-8.
159. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354: 20-5.
160. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87: 1365-71.
161. Chua KL, Hjerpe A. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol 1997; 66: 108-13.
162. Jain S, Tseng CJ, Horng SG, Soong YK, Pao CC. Negative predictive value of human papillomavirus test following conization of the cervix uteri. Gynecol Oncol 2001; 82: 177-80.
163. Lin CT, Tseng CJ, Lai CH, et al. Value of human papillomavirus deoxyribonucleic acid testing after conization in the prediction of residual disease in the subsequent hysterectomy specimen. Am J Obstet Gynecol 2001; 184: 940-5.
164. Riou G, Favre M, Jeannel D, et al. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet 1990; 335: 1171-4.
165. Higgins GD, Davy M, Roder D, Uzelin DM, Phillips GE, Burrell CJ. Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA. Lancet 1991; 338: 910-3.
166. Girardi F, Fuchs P, Haas J. Prognostic importance of human papillomavirus type 16 DNA in cervical cancer. Cancer 1992; 69: 2502-4.
167. Arends MJ, Donaldson YK, Duvall E, Wyllie AH, Bird CC. Human papillomavirus type 18 associates with more advanced cervical neoplasia than human papillomavirus type 16. Hum Pathol 1993; 24: 432-7.
168. Kobayashi Y, Yoshinouchi M, Tianqi G, et al. Presence of human papilloma virus DNA in pelvic lymph nodes can predict unexpected recurrence of cervical cancer in patients with histologically negative lymph nodes. Clin Cancer Res 1998; 4: 979-83.
169. Desai MS, Cubie HA. The HPV test in cervical screening: a brave new world? Cytopathology 2005; 16: 3-6.
170. Padilla-Paz LA. Emerging technology in cervical cancer screening: status of molecular markers. Clin Obstet Gynecol 2005; 48: 218-25.
171. Leung SW, Bedard YC. Immunocytochemical staining on ThinPrep processed smears. Mod Pathol 1996; 9: 304-6.
172. Rimm DL. Molecular biology in cytopathology: current applications and future directions. Cancer 2000; 90: 1-9.
173. Keating JT, Ince T, Crum CP. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 2001; 8: 83-92.
174. Negri G, Egarter-Vigl E, Kasal A, et al. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol 2003; 27: 187-93.
175. Sahebali S, Depuydt CE, Boulet GA, et al. Immunocytochemistry in liquid-based cervical cytology: analysis of clinical use following a cross-sectional study. Int J Cancer 2006; 118: 1254-60.
176. Cheung AN, Chiu PM, Tsun KL, Khoo US, Leung BS, Ngan HY. Chromosome in situ hybridisation, Ki-67, and telomerase immunocytochemistry in liquid based cervical cytology. J Clin Pathol 2004; 57: 721-7.
177. Yoshida T, Fukuda T, Sano T, Kanuma T, Owada N, Nakajima T. Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials. Cancer 2004; 102: 100-8.
178. Sahebali S, Depuydt CE, Segers K, et al. P16INK4a as an adjunct marker in liquid-based cervical cytology. Int J Cancer 2004; 108: 871-6.
179. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153: 1741-8.
180. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001; 25: 884-91.
181. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-84.
182. Agoff SN, Lin P, Morihara J, Mao C, Kiviat NB, Koutsky LA. p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 2003; 16: 665-73.
183. Tringler B, Gup CJ, Singh M, et al. Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol 2004; 35: 689-96.
184. Murphy N, Ring M, Killalea AG, et al. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol 2003; 56: 56-63.
185. Kalof AN, Cooper K. p16INK4a immunoexpression: surrogate marker of high-risk HPV and high-grade cervical intraepithelial neoplasia. Adv Anat Pathol 2006; 13: 190-4.
186. Pantanowitz L, Florence RR, Goulart RA, Otis CN. Trichomonas vaginalis P16 Immunoreactivity in cervicovaginal Pap tests: a diagnostic pitfall. Diagn Cytopathol 2005; 33: 210-3.
187. Ansari-Lari MA, Staebler A, Zaino RJ, Shah KV, Ronnett BM. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol 2004; 28: 160-7.
188. McCluggage WG, Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003; 22: 231-5.
189. Wajed SA, Laird PW, DeMeester TR. DNA methylation: an alternative pathway to cancer. Ann Surg 2001; 234: 10-20.
190. McCluskey LL, Chen C, Delgadillo E, Felix JC, Muderspach LI, Dubeau L. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol Oncol 1999; 72: 87-92.
191. Wong YF, Chung TK, Cheung TH, et al. Methylation of p16INK4A in primary gynecologic malignancy. Cancer Lett 1999; 136: 231-5.
192. Xue WC, Chan KY, Feng HC, et al. Promoter hypermethylation of multiple genes in hydatidiform mole and choriocarcinoma. J Mol Diagn 2004; 6: 326-34.
193. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-63.
194. Bastian PJ, Ellinger J, Schmidt D, et al. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age? Eur J Med Res 2004; 9: 523-7.
195. Henrique R, Jeronimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 2004; 46: 660-9; discussion 669.
196. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000; 24: 132-8.
197. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-9.
198. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005; 5: 223-31.
199. Cottrell SE, Laird PW. Sensitive detection of DNA methylation. Ann NY Acad Sci 2003; 983: 120-30.
200. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253-66.
201. Chan KY, Ozcelik H, Cheung AN, Ngan HY, Khoo US. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 2002; 62: 4151-6.
202. Shen DH, Chan KY, Khoo US, et al. Epigenetic and genetic alterations of p33ING1b in ovarian cancer. Carcinogenesis 2005; 26: 855-63.
203. Ahluwalia A, Yan P, Hurteau JA, et al. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol 2001; 82: 261-8.
204. Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE, Dobrovic A. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 2000; 21: 147-51.
205. Strathdee G, Appleton K, Illand M, et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001; 158: 1121-7.
206. Makarla PB, Saboorian MH, Ashfaq R, et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 2005; 11: 5365-9.
207. Wei SH, Balch C, Paik HH, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 2006; 12: 2788-94.
208. Wei SH, Chen CM, Strathdee G, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002; 8: 2246-52.
209. Spentzos D, Levine DA, Ramoni MF, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004; 22: 4700-10.
210. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115: 1503-21.
211. Esteller M, Catasus L, Matias-Guiu X, et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999; 155: 1767-72.
212. Numa F, Umayahara K, Suehiro Y, et al. New molecular tumor markers for endometrial cancer. Hum Cell 2001; 14: 272-4.
213. Arima T, Matsuda T, Takagi N, Wake N. Association of IGF2 and H19 imprinting with choriocarcinoma development. Cancer Genet Cytogenet 1997; 93: 39-47.
214. Nishimura M, Saito T, Yamasaki H, Kudo R. Suppression of gap junctional intercellular communication via 5′ CpG island methylation in promoter region of E-cadherin gene in endometrial cancer cells. Carcinogenesis 2003; 24: 1615-23.
215. Ahmed MN, Kim K, Haddad B, Berchuck A, Qumsiyeh MB. Comparative genomic hybridization studies in hydatidiform moles and choriocarcinoma: amplification of 7q21-q31 and loss of 8p12-p21 in choriocarcinoma. Cancer Genet Cytogenet 2000; 116: 10-5.
216. Kang S, Lee JM, Jeon ES, et al. RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int J Cancer 2006; 119: 1316-21.
217. Dong SM, Kim HS, Rha SH, Sidransky D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 2001; 7: 1982-6.
218. Virmani AK, Muller C, Rathi A, et al. Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 2001; 7: 584-9.
219. Nuovo GJ, Plaia TW, Belinsky SA, et al. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 1999; 96: 12754-9.
220. Narayan G, Arias-Pulido H, Koul S, et al. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer 2003; 2: 24.
221. Yang HJ, Liu VW, Wang Y, et al. Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol Oncol 2004; 93: 435-40.
222. Sova P, Feng Q, Geiss G, et al. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 114-23.
223. Xi LF, Toure P, Critchlow CW, et al. Prevalence of specific types of human papillomavirus and cervical squamous intraepithelial lesions in consecutive, previously unscreened, West-African women over 35 years of age. Int J Cancer 2003; 103: 803-9.
224. Gustafson KS, Furth EE, Heitjan DF, et al. DNA methylation profiling of cervical squamous intraepithelial lesions using liquid-based cytology specimens: an approach that utilizes receiver-operating characteristic analysis. Cancer 2004; 102: 259-68.
225. Feng Q, Balasubramanian A, Hawes SE, et al. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Ins 2005; 97: 273-82.
226. Wisman GB, Hollema H, de Jong S, et al. Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear. J Clin Oncol 1998; 16: 2238-45.
227. Xue WC, Feng HC, Tsao SW, et al. Methylation status and expression of E-cadherin and cadherin-11 in gestational trophoblastic diseases. Int J Gynecol Cancer 2003; 13: 879-88.
228. Feng H, Cheung AN, Xue WC, et al. Down-regulation and promoter methylation of tissue inhibitor of metalloproteinase 3 in choriocarcinoma. Gynecol Oncol 2004; 94: 375-82.
229. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-5.
230. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science 1995; 269: 1236-41.
231. Mabruk MJ, O'Flatharta C. Telomerase: is it the future diagnostic and prognostic tool in human cancer? Expert Rev Mol Diagn 2005; 5: 907-16.
232. Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 2003; 22: 370-80.
233. Olaussen KA, Dubrana K, Domont J, Spano JP, Sabatier L, Soria JC. Telomeres and telomerase as targets for anticancer drug development. Crit Rev Oncol Hematol 2006; 57: 191-214.
234. Pendino F, Hillion J, Dudognon C, et al. Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL. Leukemia 2006; 20: 599-603.
235. Mokbel K. The evolving role of telomerase inhibitors in the treatment of cancer. Curr Med Res Opin 2003; 19: 470-2.
236. Ibanez de Caceres I, Frolova N, Varkonyi RJ, et al. Telomerase is frequently activated in tumors with microsatellite instability. Cancer Biol Ther 2004; 3: 289-92.
237. Oh ST, Kyo S, Laimins LA. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J Virol 2001; 75: 5559-66.
238. Jeong Seo E, Jung Kim H, Jae Lee C, et al. The role of HPV oncoproteins and cellular factors in maintenance of hTERT expression in cervical carcinoma cells. Gynecol Oncol 2004; 94: 40-7.
239. Anderson S, Shera K, Ihle J, et al. Telomerase activation in cervical cancer. Am J Pathol 1997; 151: 25-31.
240. Pao CC, Tseng CJ, Lin CY, et al. Differential expression of telomerase activity in human cervical cancer and cervical intraepithelial neoplasia lesions. J Clin Oncol 1997; 15: 1932-7.
241. Iwasaka T, Zheng PS, Yokoyama M, et al. Telomerase activation in cervical neoplasia. Obstet Gynecol 1998; 91: 260-2.
242. Kyo S, Takakura M, Tanaka M, Kanaya T, Inoue M. Telomerase activity in cervical cancer is quantitatively distinct from that in its precursor lesions. Int J Cancer 1998; 79: 66-70.
243. Nakano K, Watney E, McDougall JK. Telomerase activity and expression of telomerase RNA component and telomerase catalytic subunit gene in cervical cancer. Am J Pathol 1998; 153: 857-64.
244. Shroyer KR, Thompson LC, Enomoto T, Eskens JL, Shroyer AL, McGregor JA. Telomerase expression in normal epithelium, reactive atypia, squamous dysplasia, and squamous cell carcinoma of the uterine cervix. Am J Clin Pathol 1998; 109: 153-62.
245. Snijders PJ, van Duin M, Walboomers JM, et al. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res 1998; 58: 3812-8.
246. Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 1998; 58: 1558-61.
247. Yashima K, Ashfaq R, Nowak J, et al. Telomerase activity and expression of its RNA component in cervical lesions. Cancer 1998; 82: 1319-27.
248. Zhang DK, Ngan HY, Cheng RY, Cheung AN, Liu SS, Tsao SW. Clinical significance of telomerase activation and telomeric restriction fragment (TRF) in cervical cancer. Eur J Cancer 1999; 35: 154-60.
249. ChangChien CC, Lin H, Leung SW, Hsu CY, Cho CL. Effect of acetic acid on telomerase activity in cervical intraepithelial neoplasia. Gynecol Oncol 1998; 71: 99-103.
250. Riethdorf S, Riethdorf L, Schulz G, et al. Relationship between telomerase activation and HPV 16/18 oncogene expression in squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix. Int J Gynecol Pathol 2001; 20: 177-85.
251. Jarboe EA, Liaw KL, Thompson LC, et al. Analysis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma. Oncogene 2002; 21: 664-73.
252. Kailash U, Soundararajan CC, Lakshmy R, Arora R, Vivekanandhan S, Das BC. Telomerase activity as an adjunct to high-risk human papillomavirus types 16 and 18 and cytology screening in cervical cancer. Br J Cancer 2006; 95: 1250-7.
253. Kyo S, Takakura M, Ishikawa H, et al. Application of telomerase assay for the screening of cervical lesions. Cancer Res 1997; 57: 1863-7.
254. Zheng PS, Iwasaka T, Zhang ZM, Pater A, Sugimori H. Telomerase activity in Papanicolaou smear-negative exfoliated cervical cells and its association with lesions and oncogenic human papillomaviruses. Gynecol Oncol 2000; 77: 394-8.
255. Reesink-Peters N, Helder MN, Wisman GB, et al. Detection of telomerase, its components, and human papillomavirus in cervical scrapings as a tool for triage in women with cervical dysplasia. J Clin Pathol 2003; 56: 31-5.
256. Bravaccini S, Sanchini MA, Amadori A, et al. Potential of telomerase expression and activity in cervical specimens as a diagnostic tool. J Clin Pathol 2005; 58: 911-4.
257. Oikonomou P, Mademtzis I, Messinis I, Tsezou A. Quantitative determination of human telomerase reverse transcriptase messenger RNA expression in premalignant cervical lesions and correlation with human papillomavirus load. Hum Pathol 2006; 37: 135-42.
258. Heselmeyer-Haddad K, Sommerfeld K, White NM, et al. Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol 2005; 166: 1229-38.
259. Brien TP, Kallakury BV, Lowry CV, et al. Telomerase activity in benign endometrium and endometrial carcinoma. Cancer Res 1997; 57: 2760-4.
260. Saito T, Schneider A, Martel N, et al. Proliferation-associated regulation of telomerase activity in human endometrium and its potential implication in early cancer diagnosis. Biochem Biophys Res Commun 1997; 231: 610-4.
261. Shroyer KR, Stephens JK, Silverberg SG, et al. Telomerase expression in normal endometrium, endometrial hyperplasia, and endometrial adenocarcinoma. Int J Gynecol Pathol 1997; 16: 225-32.
262. Kyo S, Kanaya T, Takakura M, Tanaka M, Inoue M. Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int J Cancer 1999; 80: 60-3.
263. Tanaka M, Kyo S, Takakura M, et al. Expression of telomerase activity in human endometrium is localized to epithelial glandular cells and regulated in a menstrual phase-dependent manner correlated with cell proliferation. Am J Pathol 1998; 153: 1985-91.
264. Oshita T, Nagai N, Ohama K. Expression of telomerase reverse transcriptase mRNA and its quantitative analysis in human endometrial cancer. Int J Oncol 2000; 17: 1225-30.
265. Brustmann H. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT), topoisomerase IIalpha expression, and apoptosis in endometrial adenocarcinoma and atypical hyperplasia. Int J Gynecol Pathol 2005; 24: 184-92.
266. Lehner R, Enomoto T, McGregor JA, et al. Quantitative analysis of telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium. Gynecol Oncol 2002; 84: 120-5.
267. Datar RH, Naritoku WY, Li P, et al. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas. Gynecol Oncol 1999; 74: 338-45.
268. Brustmann H. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Gynecol Oncol 2005; 98: 396-402.
269. Duggan BD, Wan M, Yu MC, et al. Detection of ovarian cancer cells: comparison of a telomerase assay and cytologic examination. J Natl Cancer Inst 1998; 90: 238-42.
270. Nouriani M, Bahador A, Berek JS, et al. Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. Clin Cancer Res 2004; 10: 2681-6.
271. Buttitta F, Pellegrini C, Marchetti A, et al. Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. J Clin Oncol 2003; 21: 1320-5.
272. Purev E, Soprano DR, Soprano KJ. Effect of all-trans retinoic acid on telomerase activity in ovarian cancer cells. J Exp Clin Cancer Res 2004; 23: 309-16.
273. Cheung AN, Zhang DK, Liu Y, et al. Telomerase activity in gestational trophoblastic disease. J Clin Pathol 1999; 52: 588-92.
274. Bae SN, Kim SJ. Telomerase activity in complete hydatidiform mole. Am J Obstet Gynecol 1999; 180: 328-33.
275. Eifel P, Hendrickson M, Ross J, Ballon S, Martinez A, Kempson R. Simultaneous presentation of carcinoma involving the ovary and the uterine corpus. Cancer 1982; 50: 163-70.
276. Gu J, Roth LM, Younger C, et al. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 2001; 93: 1147-52.
277. Woodruff JD, Solomon D, Sullivant H. Multifocal disease in the upper genital canal. Obstet Gynecol 1985; 65: 695-98.
278. Russell P, Bannatyne PM, Solomon HJ, Stoddard LD, Tattersall MH. Multifocal tumorigenesis in the upper female genital tract-implications for staging and management. Int J Gynecol Pathol 1985; 4: 192-210.
279. Enomoto T, Fujita M, Inoue M, et al. Analysis of clonality by amplification of short tandem repeats. Carcinomas of the female reproductive tract. Diagn Mol Pathol 1994; 3: 292-7.
280. Sawada M, Azuma C, Hashimoto K, et al. Clonal analysis of human gynecologic cancers by means of the polymerase chain reaction. Int J Cancer 1994; 58: 492-6.
281. Prat J. Clonality analysis in synchronous tumors of the female genital tract. Hum Pathol 2002; 33: 383-5.